---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-018635"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:53:49.559470+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liquidia loses court challenge to FDA's Tyvaso DPI exclusivity; cross claim still pending

## Summary
- On Feb 27, 2025, District Court denied Liquidia's summary judgment motion, affirming FDA's 3-year exclusivity for Tyvaso DPI.
- Exclusivity expiration remains May 23, 2025; decision does not change that date.
- United Therapeutics' cross claim challenging FDA's acceptance of Liquidia's amended NDA remains pending; dismissal motions not yet ruled on.
- Liquidia filed lawsuit in August 2024; this ruling is a legal setback for their NDA approval timeline.

## SEC filing metadata
- accession: 0001104659-25-018635
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465925018635/0001104659-25-018635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465925018635/tm257909d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-018635
- JSON: https://secwatch.observer/filing/0001104659-25-018635.json
- Plain text: https://secwatch.observer/filing/0001104659-25-018635.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.